BACKGROUND: Relatively few studies have analyzed the mortality of follicular lymphoma (FL) patients in comparison with a sex-and age-matched general population. This study analyzed the overall survival (OS) of patients with FL and compared their survival with the expected survival of a general population. METHODS: Patients diagnosed with FL were prospectively enrolled from 1980 to 2013. Standardized mortality ratios (SMRs) were obtained from yearly sex-and age-specific mortality rates in Spain, and OS was compared with age-and sex-matched general population data. RESULTS: A total of 1074 patients with newly diagnosed FL were enrolled. The median OS was 231 months (95% confidence interval [CI], 195-267 months). Event-free survival at 12 months (EFS12) and event-free survival at 24 months (EFS24) were associated with an increased probability of early death, with an SMR of 10.27 (95% CI, 8.26-12.77) for EFS12. The overall SMR, including all causes of death, was 2.55 (95% CI, 2.23-2.92), and it was higher for women (SMR, 3.02; 95% CI, 2.48-3.67) and young adults (SMR, 6.01; 95% CI, 3.13-11.55). More than 10 years after the diagnosis, mortality rates for FL patients were lower than those for the general population (SMR, 0.47; 95% CI, 0.28-0.78). When FL was excluded as a cause of death, the overall SMR was 1.35 (95% CI, 1.11-1.65) without a statistically significant mortality increase in the >60-year-old group in comparison with age-and sex-matched general population data. More than 15% of the patients included in the study (n 5 158) had more than 10 years of follow-up. CONCLUSIONS: EFS12 and EFS24 predict an early increase in mortality. The long-term SMR, over the course of 10 years of follow-up, shows that patients with FL have a risk of dying similar to that of a sex-and age-matched general population.
INTRODUCTION
Follicular lymphomas (FLs) are the second most common form of non-Hodgkin lymphoma in Western Europe. 1 The annual incidence of this disease has increased rapidly in the last decades from 2 to 3 cases per 100,000 in 1950 to 5.7 cases per 100,000 in 2009. The prevalence is approximately 40 per 100,000 per year. 2 Patients usually have prolonged survival; medians can reach or exceed 10 years. The rates of response to different treatments are high, although responses are followed by sequent relapses with a shrinking time interval. Several lines of evidence suggest that the prognosis of patients with FL has improved since the introduction of rituximab. The median survival has increased up to 14 years, and progression-free survival has increased up to 5 years. 3, 4 These increases in patient survival have been observed since 2003 with the introduction of chemotherapy regimens combined with rituximab.
The main goal of our study was to analyze the overall survival (OS) of patients with FL and compare it with the expected survival of the general population. Our purpose was to test the hypothesis of an eventual definitive cure for FL.
MATERIALS AND METHODS

Patients
Patients diagnosed with grade 1 to 3A FL between January 1980 and December 2013 were enrolled in the FL Registry, a prospective registry promoted by the Spanish Lymphoma Oncology Group that includes all new lymphoma cases, regardless of their histological subtype. 5 All diagnoses were confirmed by a study hematopathologist. The exclusion criteria were as follows: an initial diagnosis of grade 3B FL (n 5 23), primary cutaneous FL (n 5 12), and positivity for human immunodeficiency virus (n 5 2).
This database contains information concerning the demographic and clinicopathological features of each patient as well as prognostic factors, serum lactate dehydrogenase levels, the Eastern Cooperative Oncology Group performance status, and the type of treatment and treatment outcome (cyclophosphamide, vincristine, and prednisone or cyclophosphamide, doxorubicin, vincristine, and prednisone with or without rituximab). Patients were staged according to the Ann Arbor system, and the Follicular Lymphoma International Prognostic Index (FLIPI) was calculated. Systemic symptoms were regarded as present when the patient had unexplained fever, night sweats, or weight loss > 10% of their initial body weight, and bulky disease was defined as >7 cm. Treatment information included the type of therapy (radiation therapy, chemotherapy, combined therapy, or no therapy), the response to therapy, and the patient's survival status (assessed in months). Baseline clinical, laboratory, and treatment data were abstracted from medical records with the hospital's standard protocol. Disease progression or relapse, retreatment, and death were verified through a review of pathology and medical records. The cause of death was determined by a review of death certificates and medical records. Deaths due to disease included progressive disease, regardless of other causes of death. Deaths unrelated to lymphoma included deaths that were considered independent of the malignant lymphoma or chemotherapy treatments.
The authors served on the advisory board for this study and participated in all phases of the study, including the protocol design, data collection and analysis, and consideration of participating sites.
This study was reviewed and approved by the local ethics committee, and written informed consent was obtained from all participants.
Statistical Methodology
Data are described as means of absolute and relative frequencies for categorical variables and as means and standard deviation or medians and 25th and 75th percentiles for numerical ones.
Patient follow-up after diagnosis was ended on the earliest of the following dates: December 2013 for survivors, the date of death, or the date of the last follow-up. All-cause mortality was compared with mortality for the general population in Spain as follows: reference mortality rates by year, sex, and 5-year age groups were provided by the National Center for Epidemiology and were recorded by the National Statistics Institute. The standardized mortality ratio (SMR) was defined as the ratio of the observed number of deaths to the expected number of deaths, with the rates observed in the general population taken into account. SMRs and 95% confidence intervals (CIs) were calculated under the assumption of a Poisson distribution for deaths observed in the follow-up period. 6, 7 Results were obtained for the entire cohort and separately for sex and age groups at diagnosis and the prescription of rituximab. Because rituximab was introduced in 2005, information according to its prescription was categorized as follows: diagnosis before 2005, diagnosis after 2005 without rituximab treatment, and diagnosis after 2005 with rituximab treatment.
Given the recent clinical relevance of event-free survival at 12 months (EFS12) and event-free survival at 24 months (EFS24) as predictive indexes, 8, 9 we obtained these indexes for the cohort to estimate their association with OS. Event-free survival (EFS) was defined as the time from diagnosis until relapse or progression, unplanned retreatment of lymphoma after initial management, or death due to any cause.
To assess whether patients who did not die because of the primary tumor had a mortality rate different from that of the general population, a subgroup analysis was performed that excluded those patients who died because of the primary tumor.
The crude probability of death was estimated with the Kaplan-Meier method, and differences between patient groups were assessed with the log-rank test.
To investigate specific contributions (age, sex, period of diagnosis, rituximab treatment, and FLIPI Original Article score), we adjusted a multivariate Cox proportional hazards model for sex, the age at diagnosis (<40, 40-60, or > 60 years), the year of diagnosis/rituximab treatment (diagnosis before 2005, diagnosis in or after 2005 with no rituximab treatment, or diagnosis after 2005 with rituximab treatment), and the FLIPI score (0-1, 2, or 3-5). The assumption of the proportionality of hazards was evaluated with Schoenfeld residuals. 10 All statistical tests were 2-sided, and a P value < .05 was considered statistically significant. All analyses were performed with Stata 14.1 (StataCorp, College Station, TX).
RESULTS
Patient Characteristics
From 1980 to 2013, a total of 1178 patients with FL were diagnosed and treated at the oncology department of 17 Spanish hospitals. According to the external evaluator's criteria and because of a lack of sufficient diagnostic, survival, or follow-up data, 104 of the 1178 patients diagnosed with FL were excluded from the analysis. When the exclusion criteria were applied, 23 patients with an initial diagnosis of grade 3B FL, 12 cases with primary cutaneous FL, and 2 human immunodeficiency virus-positive cases were also discarded ( Fig. 1) . The median follow-up was 54.7 months (range, 0.1-381.8 months) for the entire series and 61.5 months (range, 0.1-381.8 months) for patients alive and free of disease. The median OS was 231 months (95% CI, 195-267 months). Of the 1074 patients, 53% were women, and the mean age at diagnosis was 58 years (standard deviation, 14 years).
The main characteristics registered at the time of diagnosis are reported in Table 1 . As for prognostic factors upon diagnosis, 44.2% of the patients were older than 60 years, 73% presented at stage III or IV, 9.2% had an Eastern Cooperative Oncology Group performance status > 1, 24% presented with a hemoglobin level < 12 mg/dL, 24.3% presented with an elevated lactate dehydrogenase level, 27.2% presented at Ann Arbor stage I or II, and almost 43% presented with more than 4 affected lymph node areas. At the time of this writing, 17% of the patients were alive with disease, 60% were alive without active macroscopic disease, and 23% were dead. 
Comparison of the Study Group and General Population Mortality Rates
The SMR was used to quantify the increase or decrease in mortality in the study cohort versus the general population. The global SMR, including all causes of death, was 2.55 (95% CI, 2.23-2.92), and this indicated that this population had, on average, double the risk of death in comparison with the general population. The cumulative probability of survival of the cohort of patients with FL and the expected cumulative probability of survival for the general population are presented in Figure 2A . In Figure 2B , the observed cumulative survival of the cohort is shown along with the expected survival of the general population (segmented into men and women).
With stratification by sex, women had a higher SMR than men (Fig. 3) . In addition, being younger than 40 years at diagnosis corresponded to an SMR of 6.01, whereas the SMRs were 3.97 for patients 40 to 60 years old and 2.14 for patients older than 60 years. The broadness of the interval for <40 years is remarkable because there were only 9 deaths observed in this subgroup. To avoid bias, data regarding the year of diagnosis and treatment with rituximab were merged; thus, patients who received rituximab were included in the group of patients diagnosed in or after 2005 (when rituximab was introduced into chemotherapy schemes), and accordingly, no patients diagnosed before 2005 were treated with rituximab. In the unadjusted analysis, these 3 subgroups presented an SMR > 1 and a CI with the unit excluded. When we segmented the cohort according to EFS12 and EFS24, much higher SMR values were observed for those patients who did not reach an EFS status at 12 and 24 months, respectively.
The analysis was repeated for a subgroup of patients that excluded those who died of the primary tumor so that we could evaluate whether other circumstances related to the disease (concomitant treatments, doses of radiation, or secondary malignancies) would make a difference with the general population death rate once mortality by FL was excluded. The results are shown in Figure 3B , and the same patterns found in Figure 3A can be observed.
Finally, Figure 4 presents SMRs in biennial intervals up to 10 years after the diagnosis and from 10 years onward. Ten years after the diagnosis, the mortality experienced by this cohort was not statistically different from the mortality of the general population (SMR, 1.02; 95% CI, 0.57-1.85), and after 10 years, it was lower than expected (SMR, 0.47; 95% CI, 0.28-0.78); in fact, the mortality rate was lower than that of the general population. SMRs according to the EFS12 and EFS24 status are depicted in Supporting Figures 1 and 2 (see online supporting information).
The long-term follow-up of patients allowed data to be obtained more than 10 years after the diagnosis of FL. More than 15% of the patients included in the study (n 5 158) had more than 10 years of follow-up, and this may have inevitably led to a decrease in the accuracy of the estimates.
Adjusted Analysis
A multivariate Cox regression was performed to assess the association of sex, age at diagnosis, year of diagnosis/rituximab treatment, and FLIPI score with all-cause mortality in the study cohort. The results are depicted in Table 2 . Although sex had no association in terms of survival, the age at diagnosis did. Patients who were 40 to 60 years old at diagnosis had a hazard ratio (HR) of 2.12 (95% CI, 1.09-4.14; P 5 .027) in comparison with those patients diagnosed before the age of 40 years. As for the year of Figure 2 . Annual cumulative probability of survival for the cohort of patients with follicular lymphoma versus the estimated probability of survival (A) for the general population and (B) with stratification by sex.
diagnosis and rituximab treatment, with those patients diagnosed before 2005 (the year in which rituximab was introduced) used as a reference group, patients who were diagnosed in or after 2005 and were not treated with rituximab did not show a statistically different mortality rate in comparison with the reference group (HR, 1.21; 95% CI, 0.61-2.41), and those treated with rituximab showed an HR of 0.53 (95% CI, 0.38-0.74; P < .001). This association was replicated when patients receiving rituximab were compared with non-rituximab-treated patients (both groups were diagnosed in or after 2005; data not shown). As for the FLIPI score, a 2-point score was associated with an increase in the HR to 1.61 (95% CI, 1.11-2.34) in comparison with a FLIPI score of 0 or 1. When the score was 3 to 5, the HR was 2.79 (95% CI, 1.94-4.00).
DISCUSSION
Classically, FL has been considered to be incurable, though with long survival times. We observed increases in the OS of patients over the years and diagnostic periods, and they were identifiable for all age and sex groups, including groups at advanced stages. This finding is consistent with data from American and European studies. [11] [12] [13] However, a constant concern with these tumors with long survival times and many treatments is that overall mortality, in comparison with that of a sex-and agematched general population, is always much higher, as occurs with Hodgkin lymphoma. 14 When we considered all causes of death in our study, these patients had twice the risk of death in comparison with a sex-and age-matched general population. Importantly, the risk was higher for women versus men. Also, the difference in mortality was higher for younger patients Figure 4 . SMRs and 95% CIs for all-cause mortality represented biennially after diagnosis (dots and vertical bars, respectively). The line and the shaded region represent the cumulative SMR and its 95% CI, respectively. CI indicates confidence interval; SMR, standardized mortality ratio Figure 3 . Forest plots of SMRs (global and by subgroups) for (A) all-cause mortality and (b) non-cause-specific mortality. The forest plots were generated with the Distiller SR forest plot generator from Evidence Partners. EFS12 indicates event-free survival at 12 months; EFS24, event-free survival at 24 months; LCL, lower confidence limit; R, rituximab; SMR, standardized mortality ratio; UCL, upper confidence limit. when we considered all deaths and excluded the tumor as a cause, and this suggests that apart from this cause, there is no other cause with the same predisposition; this is unlike other lymphomas, for which cardiovascular dysfunction or second tumors provide a constant and significant difference between the 2 populations. Nevertheless, assessing differences in all-cause mortality in the cohort, we found a statistically significant effect for rituximab treatment, as observed in the Cox regression analysis: the data show that patients receiving rituximab had a 47% decrease in the mortality rate in comparison with patients who were diagnosed before 2005 and were not treated with rituximab. This association was replicated when we compared patients receiving rituximab with non-rituximab-treated patients (both groups were diagnosed in or after 2005; data not shown).
The prognostic value of traditional scales such as FLIPI 15 was maintained in our study, with the HR being 2.7 (95% CI, 1.9-4.0) for a score of 2 to 5; this was significantly worse than the HR for lower scores, which was 1.6 (95% CI, 1.1-2.3).
For the purpose of identifying populations of patients with biologically different behaviors, tools such as EFS12 and EFS24 have been associated with an increased probability of early death. 8 Although this is a relatively new prognostic tool, its prognostic weight for the OS of FL patients is also very important in our study. EFS is defined as the time from diagnosis to progression, relapse, retreatment, or death due to any cause and provides information about patients with early progression. We know that 20% of patients have FL progression within 2 years of the first-line treatment. 16 In our study, patients who failed to achieve EFS12/ EFS24 had an SMR higher than the rest (Supporting Figs. 1 and 2 [see online supporting information]). These results are similar to those obtained in the Lyon cohort study, 9 in which the SMR was 8.74 (95% CI, 5.41-13.36), whereas in our study, it was 10.27 (95% CI, 8.26-12.77) with EFS12. This population of patients should be identified as candidates for clinical trials with new drugs targeting specific molecular pathways in FL (eg, the EZH2 pathway). 17 Few studies have analyzed FL mortality in comparison with the expected mortality of a sex-and age-matched general population. The risk for younger patients is higher according to a previous analysis 18 making no comparisons with a general population, and this reinforces the idea of moving the age in risk groups to earlier stages than the ones currently considered. 19 As a matter of fact, the excess mortality caused by tumors among women described in recent publications 20 and clinical studies without consideration of the population correlation is alarming. 21 These results differ from those recently published by Nabhan et al 22 from the LymphoCare study, which found that lymphoma-related mortality (HR, 0.46; 95% CI, 0.23-0.93) and OS (HR, 0.63; 95% CI, 0.41-0.97) favored females who were 60 years old or older. The populations do not completely overlap; this starts with the country of origin, the type of study, and the treatments received. In the population of Nabhan et al's study, women received fewer anthracyclines than men. There is no such difference in our population, and this could explain the differences in the SMR, which represents additional information over the long term. Notably, our patients received the same dose of rituximab despite their sex. In our results, regardless of the comparison with the general population, we did not find sex-related differences in OS, and it was when we made a comparison with the general population that women had a greater SMR than men. Causes other than the lymphoma itself intervened in this situation and were probably related to the hormonal situation, and this should be studied more extensively in future studies. In the Surveillance, Epidemiology, and End Results retrospective study, no statistically significant sexrelated differences were found. This is one of the strengths of comparative studies including the survival of the general population: finding differences in survival with large populations and not focusing only on the outcome of the study, which may contain confusing variables that are not possible to control. Specifically, the strengths of this study include the large series of prospectively enrolled patients in Spain, and because the study is multicenter, it avoids the risk of a selection bias. It remains unknown whether the treatments and active follow-up of the patients have resulted in a lower mortality rate for the population with lymphoma; therefore, further studies focused on the specific causes of death are needed. In any case, the results obtained to date may be relevant and should be taken into account for further investigations.
This study has, however, several limitations. A total of 104 patients were excluded because of missing data. Thus, to reduce misclassification, both the diagnosis and the disease stages were determined according to wellestablished criteria. Also, we lacked accurate data on population migration during the years between censuses, and this may have biased the estimates of population mortality rates. However, the consistency of both our findings across all age groups and the decreasing time trend suggests that these inaccuracies should not have a significant impact on the results.
In conclusion, when all causes of death were considered, the mortality rate was twice that of a sex-and agematched general population. However, more than 10 years after the diagnosis of the disease, the mortality rate was lower than that of the general population. The factors that had an impact on mortality in our study cohort were age and treatment with rituximab.
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